New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Sumitomo Pharma Co., Ltd.
DNPUF
Shape
US Flag

PNK

Unprofitable

EPS improving

Unprofitable

EPS improving

2B

Drug Manufacturers - Specialty & Generic

Next Earning date - 30 Oct 2024

2B

Drug Manufacturers - Specialty & Generic

Next Earning date - 30 Oct 2024

4.30USD
0.00 ( 0.00%)
Market Open
favorite-chart

Relative Strenght

favorite-chart

Volume Buzz

-79%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

4%

Quote Panel

Shape
Updated October 16, 2024
1W 0.00 % 1M -4.44 % 3M 49.31 % 1Y 22.86 %

Key Metrics

Shape
  • Market Cap

    1.71B


  • Shares Outstanding

    397.29M


  • Share in Float

    153.86M


  • Dividende

    0


  • Earning Date

    30 Oct 2024


  • Price Target

    4.3


  • Average Volume

    479


  • Beta

    0.613


  • Range

    1.99-4.5


  • Industry

    Drug Manufacturers - Specialty & Generic


  • Website

    https://www.sumitomo-pharma.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

0.77x

P/S Ratio

1.58x

P/B Ratio

2.4

Debt/Equity

-78.9%

Net Margin

$-4.4

EPS

How DNPUF compares to sector?

P/E Ratio

Relative Strength

Shape

DNPUF

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$327B

Shape261%

2025-Revenue

$24.15

Shape-160%

2025-EPS

$49B

Shape1186%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Citigroup

upgrade

Previous: Not converted

2024-08-08

Now: Neutral

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-96.63
vs 79.66

Q4.22

arrow
arrow

N/A

-28.24
vs 24.94

Q1.23

arrow
arrow

N/A

-140.98
vs 25.3

Q2.23

arrow
arrow

N/A

-97.81
vs 78.3

Q3.23

arrow
arrow

N/A

-72.68
vs -96.63

Q4.23

arrow
arrow

N/A

-125.77
vs -28.24

Q1.24

arrow
arrow

N/A

-496.52
vs -140.98

Q2.24

arrow
arrow

+100%

0.25
vs -97.81

Q3.24

arrow
arrow

+125%

17.82
vs -72.68

Q4.24

arrow
arrow

+115%

18.51
vs -125.77

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-2%

159.4B  vs 162.5B

Q4.22

arrow
arrow

+2%

141B  vs 138.3B

Q1.23

arrow
arrow

-26%

95.3B  vs 128B

Q2.23

arrow
arrow

-53%

75.7B  vs 159.9B

Q3.23

arrow
arrow

-52%

77B  vs 159.4B

Q4.23

arrow
arrow

-42%

82.4B  vs 141B

Q1.24

arrow
arrow

-17%

79.5B  vs 95.3B

Q2.24

arrow
arrow

+20%

90.7B  vs 75.7B

Q3.24

arrow
arrow

+13%

87.2B  vs 77B

Q4.24

arrow
arrow

+4%

85.7B  vs 82.4B

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-6%

-0.06
vs 0.05

Q4.22

arrow
arrow

-2%

-0.02
vs -0.06

Q1.23

arrow
arrow

-14%

-0.14
vs -0.02

Q2.23

arrow
arrow

-9%

-0.09
vs -0.14

Q3.23

arrow
arrow

-7%

-0.07
vs -0.09

Q4.23

arrow
arrow

-15%

-0.15
vs -0.07

Q1.24

arrow
arrow

-126%

-1.26
vs -0.15

Q2.24

arrow
arrow

+10%

0.1
vs -1.26

Institutionnal OwnershipShape

status-up

Earnings Growth

Latest News